NCT03556956View on ClinicalTrials.gov

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Masitinib

Tyrosine kinase inhibitor

Trial Locations (5)

644013

Omsk Clinical oncology dispensary, Omsk

779 00

University Hospital Olomouc, Olomouc

Unknown

Chu - Hopitaux de Rouen, Rouen

Hospital Madrid Norte San Chinarro, Madrid

Hammersmith Hospital Imperial College Healthcare Nhs Trust, London

Sponsors

Lead Sponsor

AB Science
All Listed Sponsors
lead

AB Science

INDUSTRY